World 19 (medication for COVID-19 coronavirus)

2021: Drug registration

On December 22, 2021, the Ministry of Health of the Russian Federation registered a drug for coronavirus COVID-19 under the name "World 19." It was developed by the FSBI "GNC Institute of Immunology" FMBA of Russia.

The medicine is intended for inhalation in hospital conditions. Its action is based on the use of microRNAs that block certain sites of the RNA virus, those sites that are responsible for copying the virus molecule.

World 19 (medication for COVID-19 coronavirus)

As explained by the head of the FMBA Veronika Skvortsova, the drug works at the gene (post-transcriptional) level, namely, selectively suppresses the activity of vital RNA sequences of the virus, while not affecting the human genome. Decoding the genome of the SARS-COV-2 virus made it possible to establish optimal targets inside it. The optimal bio-target is the most conserved RNA sequence of the virus, encoding the enzyme - RNA polymerase of the virus. Without this enzyme, the virus loses its ability to multiply within the body, she said.

The full identity of Mir 19 and the target in the genome of all known virus lines, including omicron, has been established. No mutations were detected. Which makes the drug universal against different options, SARS-CoV-2 said Skvortsova.

The Ministry of Health added that the effectiveness of the drug was studied in the red zone of hospitals in patients with moderate severity COVID-19. The drug showed effectiveness in comparison with standard therapy, the department noted.

Preclinical tests revealed its low toxicity, and also found that the viral load after its use decreases by 10 thousand times. During the first phase, safety and good tolerability of the drug were observed in healthy volunteers.

According to the instructions for the drug "World 19," he is contraindicated for pregnant and nursing women. The medicine is intended for the treatment of patients aged 18 to 65 years.^[1]

Notes